Jeff is an accomplished oncologist, scientist, and industry executive with extensive experience in leading global clinical development, regulatory, and medical affairs organizations. Former Executive of Oncology Development at Bristol-Myers Squibb, Pfizer, Bayer, and Kyowa Kirin, leading preclinical to late-stage development and securing multiple INDs and initial approvals for Nexavar®, Poteligeo®, Cyrsvita®, and Nourianz®. Previously served as CMO at Constellation Pharmaceuticals and other Boston-based biotech startups. Proficient in biologics and ADC development. Trained at Harvard, Johns Hopkins, and NCI, with over 60 publications.

Prior to taking the CEO role at Myris Therapeutics, Laura was executive chairperson of  BioHybrid Solutions’ board of directors, the CEO of OncXerna Therapeutics, and served in prior leadership roles at Eli Lilly and Harvard Medical School.  She is an experienced cancer and vascular biology researcher and drug developer turned biotech executive.  She is driven by a passion for improving patients’ lives through innovative drug discovery and development.

Mark Murcko has directly contributed to nine marketed drugs and several additional molecules currently in mid- to late-stage clinical trials. He has been the founding CSO and remains a board member at Dewpoint Therapeutics and Relay Therapeutics.  In addition, Mark is a senior lecturer in the Department of Biological Engineering at MIT, and has served on numerous scientific advisory boards and corporate boards of directors for a diverse range of organizations.

Krzysztof (Kris) Matyjaszewski, Ph.D., professor in the department of chemistry at the Mellon College of Science, Carnegie Mellon University, is highly regarded internationally recognized polymer chemist who has yielded significant innovations in polymer chemistry.  Amongst his many honors, awards and accomplishments, Kris is a member of the National Academy of Sciences and National Academy of Engineering.  He is perhaps best known for the discovery of atom transfer radical polymerization (ATRP), a novel method of polymer synthesis that has revolutionized the way macromolecules are made.

Alan, a co-founder of Myris, is currently Vice President, Large Molecule Discovery & Research Data Science at Amgen, leading all Amgen’s protein, ADC, and genetic medicine drug discovery programs.   Alan has broad experience at the interface of science, healthcare and commercialization. His experience includes founding and leading both the McGowan Institute for Regenerative Medicine at Pitt, as well as the Disruptive Health Technology Institute at CMU. Alan has founded a number of successful startup companies including Agentase and BioHybrid Solutions. Rolling Stone Magazine ranked Alan #32 on the “Top 100 People Who Will Change America” list!

Dr. Zweidler-McKay is an experienced Oncologist with a successful track record in the pharmaceutical industry including 8 years developing 5 ADCs for heme and solid tumors at Immunogen. Following the acquisition by Abbvie, Patrick spanned the transition to support the recent BLA submission of pivekimab sunirine/IMGN632.   Prior to Immunogen,  he spent 11 years at MD Anderson as a pediatric oncologist holding multiple leadership positions.